Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia
NCT06610760Phase 4Recruiting
- Sponsor
- Yongquan Shi
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastric intestinal metaplasia (IM) comparing The ursodeoxycholic acid group with The placebo group (2 arms). Primary endpoints: Regression rate of gastric intestinal metaplasia based on OLGIM stage at 6 months and Progression rate of gastric intestinal metaplasia based on OLGIM stage at 6 months. Started Nov 2024; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
gastric intestinal metaplasia (IM)
Beyond the preview
Go deeper on NCT06610760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610760.